DOI:
10.1055/s-00035024
Thrombosis and Haemostasis
Issue 02 ·
Volume 79 ·
1998
DOI: 10.1055/s-007-35663
Letters to the Editor
249
Perry, D. J.;
Daly, M. E.;
Tait, R. C.;
Walker, I. D.;
Brown, K.;
Beauchamp, N. J.;
Preston, F. E.;
Gyde, H.;
Harper, P. L.;
Carrell, R. W.:
Antithrombin Cambridge II (Ala384Ser): Clinical, Functional and Haplotype Analysis of 18 Families
338
Boneu, B.;
Navarro, C.;
Cambus, J. P.;
Caplain, H.;
d’Azemar, P.;
Necciari, J.;
Duret, J. P.;
Gaud, C.;
Sié, P.:
Pharmacodynamics and Tolerance of Two Nadroparin Formulations (10,250 and 20,500 Anti Xa IU·ml-1) Delivered for 10 Days at Therapeutic Dose
362
Tietze, Lothar;
Elbrecht, Anne;
Schauerte, Carsten;
Klosterhalfen, Bernd;
Amo-Takyi, Baffour;
Gehlen, Johanna;
Winkeltau, Gerd;
Mittermayer, Christian;
Handt, Stefan:
Modulation of Pro- and Antifibrinolytic Properties of Human Peritoneal Mesothelial Cells by Transforming Growth Factor β1 (TGF- β1), Tumor Necrosis Factor α (TNF-α) and Interleukin β1 (IL-1β)
431
Finkle, Carolyn D.;
Pierre, Annie St.;
Leblond, Lorraine;
Deschenes, Isabelle;
DiMaio, John;
Winocour, Peter D.:
BCH-2763, a Novel Potent Parenteral Thrombin Inhibitor, Is an Effective Antithrombotic Agent in Rodent Models of Arterial and Venous Thrombosis – Comparisons with Heparin, r-Hirudin, Hirulog, Inogatran and Argatroban
Scientific and Standardization Committee Communication